Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Explore this paper's citation graph
Summary
Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
- Type
- article
- Published
- 2009-01-01
- Cited by
- 5,330
- References
- 37
- OpenAlex
- https://openalex.org/W1994193851
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:35610395
Keywords
Sorafenib, Hepatocellular carcinoma, Placebo, Medicine, Double blind
References
- Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.
- Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.
- Sorafenib in advanced hepatocellular carcinoma.
- International trends and patterns of primary liver cancer
- Treatment modalities for hepatocellular carcinoma.
- Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials
- Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.
- Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a
- Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
- Natural History of Untreated Nonsurgical Hepatocellular Carcinoma
- New therapies for hepatocellular carcinoma
- Epidemiology of hepatocellular carcinoma in Japan
- Updated treatment approach to hepatocellular carcinoma
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors
- High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies
- Transection of the oesophagus for bleeding oesophageal varices
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
- The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa
- Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
Cited by
- Hepatocellular carcinoma: diagnosis, management, and prognosis.
- Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma
- Systemic Therapies in Hepatocellular Carcinoma
- [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
- Recent advances in the treatment of hepatocellular carcinoma
- Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
- Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report
- Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
- Phase 1‐2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
- A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma Progression
- Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
- Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma
- Superselective Transarterial Chemoembolization for Hepatocellular Carcinoma: Recent Progression and Perspective
- Clinical course of sorafenib treatment in patients with hepatocellular carcinoma
- The inhibitor of Ca2+-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB
- Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature.
- Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study
- Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90
- Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models
Related papers
- Prognostic factors in patients with hepatocellular carcinoma treated with Sorafenib
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma
- Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib
- High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Data from High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Sorafenib in hepatocellular carcinoma.
- Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.